Background: Over the past decade, several new drugs have received regulatory approval for metastatic breast cancer (mBC). However, some of these approvals were based on improvement in progression-free survival (PFS), without a concomitant increase in overall survival (OS). This has led some to question the utility of using PFS as a measure for drug approval. 
OBJECTIVES
 To perform a systematic review of the mBC randomized trial literature evaluating anthracyclines, taxanes and targeted therapies.  To assess the statistical validity of using PFS as a surrogate endpoint for OS in mBC patients receiving 1 st , 2 nd and beyond second 2 nd line chemotherapy.  To test the statistical interaction between PFS (as a surrogate endpoint for OS) and line of chemotherapy in mBC.
SYSTEMATIC LITERATURE REVIEW
 PubMed/Medline, EMBASE, and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials evaluating anthracyclines, taxanes and targeted therapies in patients with mBC published between January 1, 1990 and August 1, 2015.  There was no restriction on the line of therapy being tested in each study. Trials evaluating 1 st , 2 nd and beyond 2 nd line therapy were considered.  There was also no restriction on trials evaluating single-agent or combination therapy.  The trial must have utilized a parallel grouprandomized design with at least 65 MBC patients enrolled into each arm.  At least one of the arms must have included an anthracycline, a taxane, or a targeted therapy.  Trials evaluating hormonal therapies were not incorporated into the analysis because these agent are a different class of drugs with a unique mechanism of action.  Once trials meeting the inclusion criteria were identified, the following data were extracted: sample size, year of publication, regions involved (e. 
STATISTICAL ANALYSIS
 The two co-primary endpoints for evaluating the association between PFS and OS was the correlation between the HR for PFS (HR PFS ) and OS (HR PFS ) as well as the correlation between differences in the median PFS (Δ PFS) and OS (Δ OS) between the experimental and control arms of the trials.  Whenever HRs for PFS and OS were not reported in a given trial, they were calculated using the following formulas: HR OR = median OS in experimental group / median OS in the control group; HR PFS = median PFS in experimental group / median PFS in the control group.  For each trial that met the inclusion criteria, the association between PFS (HR PFS or Δ PFS) and OS (HR OS and Δ OS) was initially measured using the Spearman Rank Correlation Coefficient.  In two separate analyses, weighted (on the total trial sample size) multivariable regression analysis was then used to measure the association between the HR PFS (primary predictor variable) and HR OS (dependent variable). In the second analysis, Δ PFS was the main predictor variable and Δ OS was the dependent variable.  These approaches provided a measure of the model R 2 statistic, which is the proportion of variability in the dependent variable accounted for by the model.  Other independent variables considered in the regression models included line of therapy, combination vs. single agent therapy, year of trial publication, region where the study was conducted (U.S. vs. European vs. global), what the primary trial endpoint was (i.e. PFS, TTP, TTF or OS), if the PFS measurement in the trial was consistent with the current FDA definition, if the trial incorporated data censoring into the analysis, and if patient cross over was permitted from the control into the experimental arm.  The slope of the regression line of the final model provided an estimate of how much of a risk reduction (i.e. via the HR) in PFS contributes to a decrease in the risk of death for patients who were randomized into the experimental arm of the trial. In the case of the model that used Δ PFS and Δ OS as the predictor and dependent variables, the final model coefficient estimated the incremental OS benefit per incremental month of PFS reported for the experimental arm of the trial.  The stability of the base case results for each modelling analysis was then evaluated in a series of one way sensitivity analyses.
RESULTS

CONCLUSIONS
 The systematic literature search identified 72 randomized trials that fulfilled the eligibility, which provided 84 trial comparative arms, with median sample sizes in the control and experimental arms being 149 and 144 patients respectively.  The publication years spanned from 1991 to 2015, with a maximum of 11 publications in 2011. The most common progression endpoint was TTP (n=44), 33 and 7 of the trials used PFS and TTF respectively.  The univariate Spearman Rank correlation coefficient suggested a modest association between HR OS and HR PFS (Spearman's rho = 0.46; p < 0.001) as well as Δ OS and Δ PFS (Spearman's rho = 0.52; p < 0.001) (Figures 1 and 2 ). Table 2 . Multivariable regression analysis on the association between change in OS and change in PFS between groups. Table 3 . Summary of sensitivity analysis on the base case results.
Variable
 The findings of this correlative meta-analysis of prospective randomized trials were consistent with another trial-level analysis 3 and indicate that improvements in PFS are correlated with increased OS.  However, the effect appears to be driven by trials evaluating new drugs in ≥ 2 nd line setting.  PFS can be a suitable surrogate for OS in mBC randomized trials evaluating new treatments in the 2 nd line setting and beyond. The use of PFS alone as a primary trial endpoint in the 1st line setting is not recommended.
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